Pharmacokinetic optimisation of novel indole-2-carboxamide cannabinoid CB1 antagonists

The pharmacokinetic based optimisation of a novel series of indole-2-carboxamide antagonists of the cannabinoid CB1 receptor is disclosed. Compound 24 was found to be a highly potent and selective cannabinoid CB1 antagonist with high predicted human oral bioavailability.

Figure optionsDownload as PowerPoint slide